Note 12 - License and Collaboration Agreement With Related Party (Details Textual) - USD ($) |
Sep. 27, 2018 |
Dec. 31, 2018 |
|---|---|---|
| SK Group [Member] | DiaMedica [Member] | ||
| Noncontrolling Interest, Ownership Percentage by Parent | 8.40% | |
| License Agreement [Member] | Ahon Pharma [Member] | ||
| Revenue from Related Parties | $ 500,000 | |
| Collaboration Agreement, Non-refundable Payment Payable Upon Regulatory Clearance | 4,500,000 | |
| Collaboration Agreement, Additional Payment Upon Development and Sales Milestone | $ 27,500,000 | |
| Collaboration Agreement, Percent of Royalties Upon Development and Sales Milestones | 10.00% |
| X | ||||||||||
- Definition The amount of additional payment receivable upon development and sales milestone in collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition The amount of non-refundable payment receivable payable upon regulatory clearance in a collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition The percent of royalties upon development and sales milestones in a collaboration agreement. No definition available.
|
| X | ||||||||||
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|